India

Covid-19: Wrong facts, says center on media reports on SII vaccine

The central government made it clear in Thursday’s media reports that Pune-based Serum Institute of India (SII) had contracted the entire production of the vaccine against the coronovirus disease (Kovid-19) by 25 May.

Also read Serum Institute Announces Covishield Price: 600 for private, 400 for government hospitals

The center said in a press release on Thursday, “Some media reports state that SII has contracted all of its production to the center by 25 May 2021, and therefore state governments will not be able to purchase the vaccine from SII by that date. ” evening. The release further stated, “These media reports are based on erroneous facts.”

Explaining the “contract”, the government stated, “A key feature of the liberalized pricing and accelerated national Kovid-19 vaccination strategy is that vaccine manufacturers will supply 50% of their monthly Central Drugs Laboratory (CDL), issued to the government.” Dosage India will be free to supply the remaining 50% of the dose to state governments and to other than the Indian government channel. State governments are free to purchase vaccine supplements from vaccine manufacturers. “

Therefore, it is very clear that out of the total CDL dose available with any vaccine manufacturer every month, 50% of the dose will be available for other than Government of India channels.

Amid a rapid rise in daily cases of viral disease, the center announced on Monday that starting May 1, everyone who is 18 or over will be eligible for vaccination against Kovid-19. It will be the third phase of a nationwide vaccine drive, the largest globally, and began on 16 January. SII is manufacturing one of the two vaccine jabs cleared for use in India, Oxford University-AstraZeneca Schott, which is being manufactured here. As “Covishield”.

Also read What will be the changes in the Kovid-19 vaccination campaign from May 1?

The second shot is called Kovaxin, and is developed by Hyderabad-based Bharat Biotech International Limited. It is India’s first, and thus only a homemade jab against Kovid-19. Both Kovaxin and Kovishield were granted the Emergency Use Authority (EUA) in January by the Drugs Controller General of India (DCGI). Earlier this month, DCGI cleared for the third shot, Russia’s Sputnik V.

Also read India will receive Russia’s Sputnik V Kovid-19 vaccine only by the end of May

According to the dashboard of the Union Ministry of Health and Family Welfare (MoHFW) on Thursday morning, 132,330,644 doses have been given in the country thus far, including 2,211,344 in the last 24 hours.

Back to top button